Skip to main
CNTX

CNTX Stock Forecast & Price Target

CNTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Context Therapeutics Inc., a clinical-stage biopharmaceutical company focused on innovative treatments for hormone-dependent cancers, has indicated that initial dose escalation data for its lead program, CTIM-76, shows promising clinical activity and safety, supporting further enrollment across various solid tumors. The company's financial position appears robust enough to sustain operations through critical clinical readouts anticipated in 2026, thereby alleviating immediate financing concerns and maintaining investor interest driven by data outcomes. With CTIM-76's demonstrated potency and selectivity for CLDN6, the potential for superior anti-tumor activity could enhance the company's valuation and attract partnership opportunities, further solidifying a positive outlook for the stock.

Bears say

Context Therapeutics Inc. has experienced a significant decline in cash reserves, finishing 2025 with $66.0 million compared to $94.4 million at the end of 2024, indicating potential financial instability. The company reported a net loss of $9.7 million for Q3 2025, despite reduced research and development expenses, and forecasts suggest a need for approximately $250 million in additional financing through 2041. Furthermore, Context faces multiple operational risks, including safety concerns in clinical programs, competitive pressures in the market, regulatory hurdles, and a risk of stock delisting if trading conditions do not improve.

CNTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Context Therapeutics LLC (CNTX) Forecast

Analysts have given CNTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, CNTX has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Context Therapeutics LLC (CNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.